title: Control of in vivo collateral damage generated by T cell immunity.
abstract: An ongoing dilemma faced during an immune response is generating an effective, often proinflammatory response to eliminate pathogens and/or infected cells while also minimizing collateral damage to adjacent noninfected tissues. The factors limiting bystander cell injury during an Ag-specific immune response in vivo are largely unknown. In this study, using an in vivo model of islet transplants in TCR transgenic mice, we show that both CD4 and CD8 T cells do have the capacity to inflict adjacent tissue damage and that this injury is greatly enhanced in sensitized hosts. CD4 T cell-mediated killing of specific and bystander cells occurred via different mechanisms. Unlike specific target cell killing, CD4-mediated bystander injury required tissue Fas expression and was inhibited with anti-IFN-γ Ab treatment in vivo. Moreover, bystander cell injury was not entirely nonspecific but rather required, in naive recipients, that the MHC allele expressed by the bystanders was self. Importantly, the coinhibitor programmed death-1 plays an important role in restraining bystander cell injury mediated either by defined TCR transgenic T cells or by polyclonal T cell populations. Thus, the differential requirements for specific versus bystander cell injury suggest that there are opportunities for inhibiting immune pathology without compromising Ag-specific immunity in vivo.
authors.affiliation: Department of Surgery, University of Alberta, Edmonton, Alberta T6G 2E1, Canada.
authors.forename: Govindarajan
authors.initials: G
authors.lastname: Thangavelu
authors.forename: Ronald G
authors.initials: RG
authors.lastname: Gill
authors.forename: Louis
authors.initials: L
authors.lastname: Boon
authors.forename: Kristofor K
authors.initials: KK
authors.lastname: Ellestad
authors.forename: Colin C
authors.initials: CC
authors.lastname: Anderson
mesh_terms: D000818:Animals; D024201:Bystander Effect / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D003921:Diabetes Mellitus, Experimental / Q000601:surgery; D005260:Female; D006183:H-2 Antigens / Q000276:immunology; D007111:Immunity, Cellular; D007114:Immunization; D007249:Inflammation; D007371:Interferon-gamma / Q000037:antagonists & inhibitors / Q000502:physiology; D016381:Islets of Langerhans Transplantation / Q000276:immunology* / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D018448:Models, Immunological; D010047:Ovalbumin / Q000276:immunology; D061026:Programmed Cell Death 1 Receptor; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D019014:fas Receptor / Q000276:immunology
chemical_list: C491899:Fas protein, mouse; D006183:H-2 Antigens; C491383:Pdcd1 protein, mouse; D061026:Programmed Cell Death 1 Receptor; D019014:fas Receptor; D007371:Interferon-gamma; D010047:Ovalbumin